公开(公告)号：US20230340106A1

公开(公告)日：2023-10-26

申请号：US17946941

申请日：2022-09-16

Applicant: Pfizer Inc. ,  The Regents of the University of California ,  The Board of Trustees of the Leland Stanford Junior University

Inventor： Isaac J. Rondon ,  Natasha Crellin ,  Paul Bessette ,  Eleonora Trotta ,  Jeffrey A. Bluestone ,  Lauren K. Ely ,  Kenan C. Garcia

IPC: C07K16/24

CPC classification number: C07K16/246 ,  C07K2317/76 ,  C07K2317/21 ,  C07K2317/51 ,  A61K2039/505

Abstract: The present invention provides antibodies, or antigen-binding portions thereof, which specifically bind to IL-2 and reduce the affinity of IL-2 binding to IL-2Rα and IL-2Rβ. The invention further provides a method of obtaining such antibodies and nucleic acids encoding the same. The invention further relates to compositions and therapeutic methods for use of these antibodies for the treatment and/or prevention of autoimmune diseases, disorders or conditions and for immunosuppression, including, but not limited to, administering a complex comprising the antibody and IL-2.

公开(公告)号：US20230263960A1

公开(公告)日：2023-08-24

申请号：US18016184

申请日：2021-07-12

Applicant: PFIZER INC.

Inventor： Ozi BEN-ARI

IPC: A61M5/315 ,  A61B90/98

CPC classification number: A61M5/31566 ,  A61B90/98

Abstract: The invention relates to a computer-controlled injector, comprising: a housing configured to receive a medicament cartridge; an injection drive mechanism comprising a computer-controlled motor for driving a piston within said medicament cartridge, for injecting the medicament; a data tag attachable to said medicament cartridge; and an electromagnetic detector disposed within said housing and being connectable to the data tag upon mounting of said medicament cartridge into said housing, said electromagnetic detector permitting data to be read from or written to said data tag. The electromagnetic detector is configured to read or write data irrespectively of a rotational orientation of said medicament cartridge within said computer-controlled injector.

公开(公告)号：US11712480B2

公开(公告)日：2023-08-01

申请号：US16321695

申请日：2017-07-31

Applicant: PFIZER INC.

Inventor： Russell George Dushin ,  Daniel P. Uccello ,  Jeremy Starr ,  Ye Che ,  Mark Flanagan ,  Jeffrey M. Casavant ,  Christopher John O'Donnell ,  Gary Frederick Filzen ,  Jennifer Young ,  Joseph A. Abramite ,  Lawrence N. Tumey ,  Ludivine Moine ,  Adam Matthew Gilbert ,  Lee R. Roberts

IPC: A61K47/54 ,  A61K47/68 ,  C07K4/00 ,  C07K5/02 ,  C07K7/02 ,  A61K47/50 ,  C07K5/062

CPC classification number: A61K47/6855 ,  A61K47/50 ,  A61K47/545 ,  A61K47/6867 ,  C07K4/00 ,  C07K5/0205 ,  C07K5/06052 ,  C07K7/02

Abstract: The present invention is directed to novel heteroaryl sulfone-based conjugation handles of the formula:




(wherein R1, R2, Het, D, E, X, Y, Z, m, n, p, q, r, s and t are as defined herein), methods for their preparation, their use in synthesizing antibody drug conjugates, and the resulting antibody drug conjugates made with components having heteroaryl sulfone-based conjugation handles.

公开(公告)号：US20230192654A1

公开(公告)日：2023-06-22

申请号：US17969479

申请日：2022-10-19

Applicant: PFIZER, INC.

Inventor： Lei Zhang ,  Erik Alphie LaChapelle ,  Christopher Ryan Butler ,  Natasha Mariam Kablaoui ,  Michael Aaron Brodney ,  Laura Ann McAllister ,  Qingyi Yang ,  Christopher John Helal ,  Damien Webb

IPC: C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/107

CPC classification number: C07D401/14 ,  C07D401/12 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D491/107

Abstract: The present invention provides, in part, compounds of Formula I: or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: X1, X2, R1, R2, m and n are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.

公开(公告)号：US11673953B2

公开(公告)日：2023-06-13

申请号：US16802822

申请日：2020-02-27

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Yi Zhang ,  Thomas John Van Blarcom ,  Siler Panowski ,  Silvia K. Tacheva-Grigorova ,  Barbra Johnson Sasu

IPC: C07K16/28 ,  A61P35/00 ,  A61K39/00 ,  C12N15/63

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K16/2887 ,  C12N15/63 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/70

Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

公开(公告)号：US11673890B2

公开(公告)日：2023-06-13

申请号：US17034295

申请日：2020-09-28

Applicant: Pfizer Inc.

Inventor： Mary Theresa Didiuk ,  Robert Lee Dow ,  David Andrew Griffith

IPC: A61K31/435 ,  C07D471/10 ,  C07D491/20 ,  C07D519/00 ,  A61K31/438 ,  A61K31/519 ,  A61K45/06 ,  C07D487/10

CPC classification number: C07D471/10 ,  A61K31/435 ,  A61K31/438 ,  A61K31/519 ,  A61K45/06 ,  C07D487/10 ,  C07D491/20 ,  C07D519/00

Abstract: The invention provides a compound of Formula (1)




or a pharmaceutically acceptable salt of the compound, wherein R1, R2, R3, Z, A1, L and A2 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

公开(公告)号：US20230174522A1

公开(公告)日：2023-06-08

申请号：US17946101

申请日：2022-09-16

Applicant: Pfizer Inc. ,  CTXT PTY LTD

Inventor： Ylva Elisabet Bergman Bozikis ,  Oleg Brodsky ,  Michelle Ang Camerino ,  Samantha Elizabeth Greasley ,  Robert Louis Hoffman ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Paul Francis Richardson ,  Paul Anthony Stupple ,  Scott Channing Sutton

IPC: C07D413/06 ,  A61P35/04

CPC classification number: C07D413/06 ,  A61P35/04 ,  A61K45/06

Abstract: The present invention relates to compounds of formula (I)




or pharmaceutically acceptable salts thereof, wherein Ring A, R1-R8, and n are defined herein. The novel benzisoxazole sulfonamide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in patients. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in patients.

公开(公告)号：US20230167069A1

公开(公告)日：2023-06-01

申请号：US18160442

申请日：2023-01-27

Applicant: Pfizer Inc.

Inventor： Elaine GREER ,  Stephen ANDERSON ,  Mark MALONEY ,  Shu YU ,  Ekaterina ALBERT ,  Emily RIGSBEE

IPC: C07D233/88

CPC classification number: C07D233/88 ,  C07B2200/13 ,  A61K31/40

Abstract: The present disclosure relates to: a) solid state forms of hydrobromide salts of Compound 1; b) pharmaceutical compositions comprising one or more solid state forms of hydrobromide salts of Compound 1, and, optionally, a pharmaceutically acceptable carrier; c) methods of treating tumors or cancers by administering one or more solid state forms of hydrobromide salts of Compound 1 to a subject in need thereof; and d) methods for the preparation of solid state forms of Compound 1.

公开(公告)号：US20230165977A1

公开(公告)日：2023-06-01

申请号：US17997312

申请日：2021-04-22

Applicant: Pfizer Inc.

Inventor： Paola Leone ,  Jeremy Francis ,  Basel T. Assaf ,  Shoh Asano ,  Kathrine Hales ,  Allison P. Berg

IPC: A61K48/00 ,  C12N9/80 ,  C12N15/86 ,  A61P25/28

CPC classification number: A61K48/0066 ,  C12N9/80 ,  C12Y305/01015 ,  C12N15/86 ,  A61P25/28 ,  C12N2750/14121 ,  C12N2750/14143 ,  C12N2750/14171 ,  C12N2800/22

Abstract: The present disclosure relates to recombinant nucleic acids and gene therapy vectors comprising a modified nucleic acid encoding aspartoacylase (ASPA), and variants thereof, for use in the treatment of diseases and disorders associated with a deficiency or dysfunction of ASPA, and in particular, Canavan disease.

公开(公告)号：US11661419B2

公开(公告)日：2023-05-30

申请号：US17126358

申请日：2020-12-18

Applicant: Pfizer Inc.

Inventor： Scott William Bagley ,  Agustin Casimiro-Garcia ,  Xiayun Cheng ,  Jennifer Elizabeth Davoren ,  Rajiah Aldrin Denny ,  Brian Stephen Gerstenberger ,  Frank Eldridge Lovering ,  Mihir Dineshkumar Parikh ,  Joseph Walter Strohbach ,  John Isidro Trujillo

IPC: C07D413/14 ,  A61P17/00 ,  A61K45/06

CPC classification number: C07D413/14 ,  A61K45/06 ,  A61P17/00

Abstract: The invention relates to benzimidazoles of Formula (I)




and pharmaceutically acceptable salts thereof, wherein R1 to R6 are as defined in the description; to their use in medicine; to compositions containing them; to processes for their preparation; and to intermediates used in such processes.

The benzimidazoles of Formula (I) are ITK inhibitors and are therefore potentially useful in the treatment of a wide range of disorders including, atopic dermatitis.